Former Silk Road Medical COO Joins ONWARD Medical’s Board

ONWARD Medical N.V. has appointed Lucas Buchanan as a non-executive member of its Board of Directors.

“We are delighted to welcome Lucas Buchanan to our Board of Directors,” ONWARD Medical CEO Dave Marver stated. “Lucas has a unique and valuable set of experiences as an operator, investor, and leader. He has also successfully NASDAQ-listed, scaled, and exited a medical technology company. He is ideally qualified to join our board as we grow our business and pursue our mission.”

Buchanan has more than 25 years of expertise in commercialization, operations, business development, investing, and finance. As the chief operating officer and chief financial officer at Silk Road Medical, he helped lead the company from its founding through to its IPO in 2019 and ultimate sale to Boston Scientific Corp. last year. Buchanan previously worked at The Vertical Group, Impax Laboratories, Warburg Pincus, Medtronic, and Ernst & Young.

Buchanan is an active investor who currently serves on the boards of several medical technology companies, including Element Science, Aerin Medical, Route 92 Medical, Procyrion, and Endologix. He earned a bachelor of arts degree in economics from Duke University and an MBA in Health Care Management from The Wharton School at the University of Pennsylvania.

“ONWARD is a truly unique company powered by an inspiring vision and breathtaking technology. The company is delivering hope to people with spinal cord injury and other movement disabilities,” Buchanan stated. “I look forward to helping Dave and the team pursue its ambitions for the benefit of millions of people around the globe.”

ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities. Building on more than a decade of scientific discovery, preclinical research, and clinical studies conducted at hospitals, rehabilitation clinics, and neuroscience laboratories, the company has developed ARC Therapy, which has been awarded 10 Breakthrough Device Designations from the U.S. Food and Drug Administration (FDA). ONWARD Medical’s ARC-EX System is cleared for commercial sale in the United States. In addition, the company is developing an investigational implantable system called ARC-IM with and without an implanted brain-computer interface (BCI).

Headquartered in the Netherlands, ONWARD Medical has a Science and Engineering Center in Switzerland and a U..S. office in Boston. The company is listed on Euronext Paris, Brussels, and Amsterdam, and its U.S. ADRs can be traded on OTCQX.